Q32 BIO INC Financials
Q32 BIO INC (QTTB) reported $53.7M in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Q32 Bio's FY2025 profit rebound masks a cash-burning, asset-light model that still consumed $33.5M .
Net income swung from-$53.7M in FY2023 to$29.8M in FY2025. But operating cash flow stayed at-$33.5M and free cash flow was also-$33.5M , so the earnings turnaround did not become cash and was not driven by heavy reinvestment.
With
Between FY2024 and FY2025, total liabilities fell from
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Q32 BIO INC's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Q32 BIO INC scores 12.41, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($475.4M) relative to total liabilities ($19.8M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Q32 BIO INC passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Q32 BIO INC used $1.13 of operating cash (-$33.5M OCF vs $29.8M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Q32 BIO INC earns $16.02 in operating income for every $1 of interest expense ($16.9M vs $1.1M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Q32 BIO INC generated $53.7M in revenue in fiscal year 2025.
Q32 BIO INC's EBITDA was $17.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 126.4% from the prior year.
Q32 BIO INC reported $29.8M in net income in fiscal year 2025. This represents an increase of 162.5% from the prior year.
Cash & Balance Sheet
Q32 BIO INC recorded an outflow of $33.5M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 50.5% from the prior year.
Q32 BIO INC held $48.3M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Q32 BIO INC's operating margin was 31.4% in fiscal year 2025, reflecting core business profitability.
Q32 BIO INC's net profit margin was 55.5% in fiscal year 2025, showing the share of revenue converted to profit.
Q32 BIO INC's ROE was 70.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 911.5 percentage points from the prior year.
Not reported for fiscal year 2025.
Capital Allocation
Q32 BIO INC invested $19.2M in research and development in fiscal year 2025. This represents a decrease of 60.2% from the prior year.
Q32 BIO INC reported no capital expenditure in fiscal year 2025. This represents a decrease of 100.0% from the prior year.
Not reported for fiscal year 2025.
QTTB Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $53.7M | $0-100.0% | $1.2M-64.0% | $3.2M-90.6% | $34.0M+1157.3% | $2.7M+62.2% | $1.7M-68.7% | $5.3M | N/A |
| R&D Expenses | N/A | $19.2M-60.2% | $48.1M+51.7% | $31.7M-67.7% | $98.4M+5.7% | $93.1M-7.3% | $100.4M+12.3% | $89.4M+86.4% | $47.9M+124.3% | $21.4M |
| SG&A Expenses | N/A | $17.7M-1.6% | $18.0M+81.9% | $9.9M-74.1% | $38.1M+3.5% | $36.8M+13.1% | $32.6M+46.7% | $22.2M+28.4% | $17.3M+109.0% | $8.3M |
| Operating Income | N/A | $16.9M+125.6% | -$66.1M-37.0% | -$48.3M+63.8% | -$133.3M-38.9% | -$95.9M+26.3% | -$130.3M-18.5% | -$109.9M-83.5% | -$59.9M-102.1% | -$29.7M |
| Interest Expense | N/A | $1.1M-62.7% | $2.8M+88.8% | $1.5M | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | $0-100.0% | $21K-93.4% | $318K-55.5% | $715K | $0 | $0 | $0 | $0 | $0 |
| Net Income | N/A | $29.8M+162.5% | -$47.7M+11.2% | -$53.7M-972.9% | -$5.0M+94.8% | -$95.8M+25.6% | -$128.7M-23.8% | -$103.9M-87.0% | -$55.6M-85.3% | -$30.0M |
| EPS (Diluted) | — | $2.42 | -$6.58 | -$153.96 | -$0.09+94.8% | -$1.73 | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
QTTB Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $61.8M-33.1% | $92.3M+96.2% | $47.1M-79.4% | $228.5M+7.9% | $211.7M-19.7% | $263.7M-15.1% | $310.6M+19.9% | $259.1M+88.4% | $137.5M |
| Current Assets | $55.0M-32.8% | $81.9M+185.1% | $28.7M-84.1% | $181.0M-5.7% | $191.9M-12.6% | $219.6M-17.6% | $266.6M+20.3% | $221.7M+68.4% | $131.6M |
| Cash & Equivalents | $48.3M-38.1% | $78.0M+204.3% | $25.6M-24.6% | $34.0M-68.6% | $108.4M-50.2% | $217.4M+304.3% | $53.8M+40.7% | $38.2M-25.9% | $51.6M |
| Total Liabilities | $19.8M-77.2% | $86.7M-62.3% | $230.0M-36.0% | $359.2M+753.8% | $42.1M-37.9% | $67.7M+30.1% | $52.1M-17.0% | $62.7M-64.6% | $177.0M |
| Current Liabilities | $11.3M-31.1% | $16.5M+16.7% | $14.1M-37.5% | $22.6M+31.1% | $17.2M-24.0% | $22.7M+83.1% | $12.4M-45.1% | $22.5M+154.1% | $8.9M |
| Total Equity | $42.0M+640.3% | $5.7M+103.1% | -$182.9M-39.9% | -$130.7M-177.0% | $169.7M-13.4% | $196.0M-24.2% | $258.5M+31.7% | $196.4M+597.7% | -$39.5M |
| Retained Earnings | -$205.0M+12.7% | -$234.8M-25.5% | -$187.1M+56.4% | -$429.1M-1.2% | -$424.1M-29.2% | -$328.4M-64.5% | -$199.7M-108.5% | -$95.8M-138.3% | -$40.2M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
QTTB Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$19.8M | -$33.5M+50.5% | -$67.7M-262.6% | -$18.7M+83.6% | -$113.7M-3.6% | -$109.8M-16.3% | -$94.3M-3.3% | -$91.4M-114.6% | -$42.6M-756.9% | $6.5M |
| Capital Expenditures | N/A | $0-100.0% | $75K+1400.0% | $5K-99.6% | $1.3M-46.4% | $2.4M-35.8% | $3.7M-82.9% | $21.8M-12.5% | $24.9M+1173.7% | $2.0M |
| Free Cash Flow | N/A | -$33.5M+50.5% | -$67.8M-262.9% | -$18.7M+83.7% | -$114.9M-2.5% | -$112.1M-14.4% | -$98.1M+13.4% | -$113.2M-67.7% | -$67.5M-1593.1% | $4.5M |
| Investing Cash Flow | $7.0M | $7.0M-64.9% | $19.9M+398600.0% | -$5K-100.0% | $36.7M+172.3% | -$50.8M-124.8% | $204.9M+495.6% | -$51.8M+57.5% | -$121.8M-49.4% | -$81.5M |
| Financing Cash Flow | $64.3M | -$3.1M-103.3% | $95.1M+23333.0% | $406K-31.9% | $596K-98.9% | $52.2M-1.7% | $53.1M-66.4% | $158.2M+4.8% | $151.0M+31.0% | $115.2M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
QTTB Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 31.4% | N/A | -4174.3% | -4154.6% | -282.4% | -4821.0% | -6599.2% | -1126.0% | N/A |
| Net Margin | 55.5% | N/A | -4645.3% | -156.0% | -281.9% | -4762.9% | -6237.4% | -1044.3% | N/A |
| Return on Equity | 70.9%+911.5pp | -840.5% | N/A | N/A | -56.5%+9.2pp | -65.7%-25.5pp | -40.2%-11.9pp | -28.3% | N/A |
| Return on Assets | 48.2%+99.9pp | -51.7%+62.5pp | -114.1%-111.9pp | -2.2%+43.0pp | -45.2%+3.6pp | -48.8%-15.3pp | -33.5%-12.0pp | -21.4%+0.4pp | -21.8% |
| Current Ratio | 4.85-0.1x | 4.97+2.9x | 2.04-6.0x | 8.02-3.1x | 11.14+1.5x | 9.69-11.9x | 21.54+11.7x | 9.84-5.0x | 14.85 |
| Debt-to-Equity | 0.47-14.8x | 15.27 | N/A | N/A | 0.25-0.1x | 0.35+0.1x | 0.20-0.1x | 0.32 | N/A |
| FCF Margin | -62.4% | N/A | -1616.1% | -3583.1% | -330.1% | -3629.4% | -6794.2% | -1268.3% | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Q32 BIO INC Ranks
Frequently Asked Questions
What is Q32 BIO INC's annual revenue?
Q32 BIO INC (QTTB) reported $53.7M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Q32 BIO INC profitable?
Yes, Q32 BIO INC (QTTB) reported a net income of $29.8M in fiscal year 2025, with a net profit margin of 55.5%.
What is Q32 BIO INC's EBITDA?
Q32 BIO INC (QTTB) had EBITDA of $17.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Q32 BIO INC's operating margin?
Q32 BIO INC (QTTB) had an operating margin of 31.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Q32 BIO INC's net profit margin?
Q32 BIO INC (QTTB) had a net profit margin of 55.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Q32 BIO INC's return on equity (ROE)?
Q32 BIO INC (QTTB) has a return on equity of 70.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Q32 BIO INC's free cash flow?
Q32 BIO INC (QTTB) recorded an outflow of $33.5M in free cash flow during fiscal year 2025. This represents a 50.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Q32 BIO INC's operating cash flow?
Q32 BIO INC (QTTB) recorded an outflow of $33.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Q32 BIO INC's total assets?
Q32 BIO INC (QTTB) had $61.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Q32 BIO INC's capital expenditures?
Q32 BIO INC (QTTB) reported no capital expenditure during fiscal year 2025.
How much does Q32 BIO INC spend on research and development?
Q32 BIO INC (QTTB) invested $19.2M in research and development during fiscal year 2025.
What is Q32 BIO INC's current ratio?
Q32 BIO INC (QTTB) had a current ratio of 4.85 as of fiscal year 2025, which is generally considered healthy.
What is Q32 BIO INC's debt-to-equity ratio?
Q32 BIO INC (QTTB) had a debt-to-equity ratio of 0.47 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Q32 BIO INC's return on assets (ROA)?
Q32 BIO INC (QTTB) had a return on assets of 48.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Q32 BIO INC's cash runway?
Based on fiscal year 2025 data, Q32 BIO INC (QTTB) had $48.3M in cash against an annual operating cash burn of $33.5M. This gives an estimated cash runway of approximately 17 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Q32 BIO INC's Altman Z-Score?
Q32 BIO INC (QTTB) has an Altman Z-Score of 12.41, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Q32 BIO INC's Piotroski F-Score?
Q32 BIO INC (QTTB) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Q32 BIO INC's earnings high quality?
For every $1 of reported earnings, Q32 BIO INC (QTTB) used $1.13 of operating cash (-$33.5M OCF vs $29.8M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Q32 BIO INC cover its interest payments?
Q32 BIO INC (QTTB) has an interest coverage ratio of 16.02x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Q32 BIO INC?
Q32 BIO INC (QTTB) scores 81 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.